MiR-26a performs converse roles in proliferation and metastasis of different gastric cancer cells via regulating of PTEN expression

Pathology Research and Practice

Volumn 213, Issue 5, 2017, Pages 467-475

  Ding, Keshuo ^a   Wu, Zhengsheng ^a   Wang, Nana ^a   Wang, Xiaonan ^a   Wang, Yuejun ^a   Qian, Pengxu ^b   Meng, Gang ^a   Tan, Sheng ^b  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Gastric cancer; Metastasis; MiR 26a; Proliferation; PTEN

Indexed keywords

MESSENGER RNA; MICRORNA 26A; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; MICRORNA; MIRN26A MICRORNA, HUMAN; PTEN PROTEIN, HUMAN;

3' UNTRANSLATED REGION; AGS CELL LINE; ARTICLE; BINDING SITE; CANCER SURVIVAL; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CORRELATIONAL STUDY; GASTRIC CANCER CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; MKN 28 CELL LINE; OVERALL SURVIVAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; DISEASE EXACERBATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM METASTASIS; PROGNOSIS; PTEN PHOSPHOHYDROLASE; STOMACH NEOPLASMS;

EID: 85013653629     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2017.01.026     Document Type: Article

References (51)

1. [1] Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. Ca-Cancer J. Clin. 61 (2011), 69–90.
2. [2] Brenner, H., Rothenbacher, D., Arndt, V., Epidemiology of stomach cancer. Methods Mol. Biol. 472 (2009), 467–477.
3. [3] Yu, H.G., Ai, Y.W., Yu, L.L., Zhou, X.D., Liu, J., Li, J.H., Xu, X.M., Liu, S., Chen, J., Liu, F., Qi, Y.L., Deng, Q., Cao, J., Liu, S.Q., Luo, H.S., Yu, J.P., Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death. Int. J. Cancer 122 (2008), 433–443.
4. [4] Bandres, E., Bitarte, N., Arias, F., Agorreta, J., Fortes, P., Agirre, X., Zarate, R., Diaz-Gonzalez, J.A., Ramirez, N., Sola, J.J., Jimenez, P., Rodriguez, J., Garcia-Foncillas, J., microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin. Cancer Res. 15 (2009), 2281–2290.
5. [5] Chun-Zhi, Z., Lei, H., An-Ling, Z., Yan-Chao, F., Xiao, Y., Guang-Xiu, W., Zhi-Fan, J., Pei-Yu, P., Qing-Yu, Z., Chun-Sheng, K., MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer, 10, 2010, 367.
6. [6] Rojo, F., Tabernero, J., Albanell, J., Van Cutsem, E., Ohtsu, A., Doi, T., Koizumi, W., Shirao, K., Takiuchi, H., Ramon y Cajal, S., Baselga, J., Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J. Clin. Oncol. 24 (2006), 4309–4316.
7. [7] Wen, L., Cheng, F., Zhou, Y., Yin, C., MiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2. Saudi J. Gastroenterol. 21 (2015), 313–319.
8. [8] Cervantes, A., Roda, D., Tarazona, N., Rosello, S., Perez-Fidalgo, J.A., Current questions for the treatment of advanced gastric cancer. Cancer Treatment Rev. 39 (2013), 60–67.
9. [9] Esquela-Kerscher, A., Slack, F.J., Oncomirs – microRNAs with a role in cancer. Nat. Rev. Cancer 6 (2006), 259–269.
10. [10] Kasinski, A.L., Slack, F.J., Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 11 (2011), 849–864.
11. [11] Bartel, D.P., MicroRNAs: genomics biogenesis, mechanism, and function. Cell 116 (2004), 281–297.
12. [12] Bartel, D.P., MicroRNAs: target recognition and regulatory functions. Cell 136 (2009), 215–233.
13. [13] Li, W., Zhang, J., Chen, T., Yin, P., Yang, J., Cao, Y., miR-132 upregulation promotes gastric cancer cell growth through suppression of FoxO1 translation. Tumour Biol., 2015 Aug 23. [Epub ahead of print].
14. [14] Tsai, M.M., Wang, C.S., Tsai, C.Y., Chen, C.Y., Chi, H.C., Tseng, Y.H., Chung, P.J., Lin, Y.H., Chung, I.H., Lin, K.H., MicroRNA-196a/-196b promote cell metastasis via negative regulation of radixin in human gastric cancer. Cancer Lett. 351 (2014), 222–231.
15. [15] Mao, S., He, N., Xin, L., Zeng, F., Cao, J., Effect of antisense miR-224 on gastric cancer cell proliferation and apoptosis. Zhonghua Zhong Liu Za Zhi [Chinese J. Oncol.] 36 (2014), 92–96.
16. [16] Sekar, D., Krishnan, R., Thirugnanasambantham, K., Rajasekaran, B., Islam, V.I.H., Sekar, P., Significance of microRNA 21 in gastric cancer. Clin. Res. Hepatol. Gas 40 (2016), 538–545.
17. [17] Duan, Y., Hu, L., Liu, B., Yu, B., Li, J., Yan, M., Yu, Y., Li, C., Su, L., Zhu, Z., Xiang, M., Yang, Q., Tumor suppressor miR-24 restrains gastric cancer progression by downregulating RegIV. Mol. Cancer, 13, 2014, 127.
18. [18] Kang, W., Tong, J.H., Lung, R.W., Dong, Y., Yang, W., Pan, Y., Lau, K.M., Yu, J., Cheng, A.S., To, K.F., let-7b/g silencing activates AKT signaling to promote gastric carcinogenesis. J. Transl. Med., 12, 2014, 281.
19. [19] Zhang, Z.L., Sun, J.L., Bai, Z.H., Li, H.J., He, S.C., Chen, R., Che, X.M., MicroRNA-153 acts as a prognostic marker in gastric cancer and its role in cell migration and invasion. Oncotargets Ther. 8 (2015), 357–364.
20. [20] Wu, Z.M., Wang, H.G., Fang, S.Y., Xu, C.Y., MiR-449c inhibits gastric carcinoma growth. Life Sci. 137 (2015), 14–19.
21. [21] Xu, X.C., Zhang, Y.H., Zhang, W.B., Li, T., Gao, H., Wang, Y.H., MicroRNA-133a functions as a tumor suppressor in gastric cancer. J. Biol. Regul. Homeost. Agents 28 (2014), 615–624.
22. [22] Tan, S., Ding, K.S., Li, R., Zhang, W.J., Li, G.P., Kong, X.J., Qian, P.X., Lobie, P.E., Zhu, T., Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2. Breast Cancer Res., 16, 2014.
23. [23] Gao, J., Li, L.S., Wu, M.Q., Liu, M., Xie, X.H., Guo, J.L., Tang, H.L., Xie, X.M., MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLoS One, 8, 2013.
24. [24] Liu, P., Tang, H., Chen, B., He, Z., Deng, M., Wu, M., Liu, X., Yang, L., Ye, F., Xie, X., miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer. Cancer Lett. 357 (2015), 384–392.
25. [25] Yang, X., Zhang, X.F., Lu, X., Jia, H.L., Liang, L., Dong, Q.Z., Ye, Q.H., Qin, L.X., MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology 59 (2014), 1874–1885.
26. [26] Wang, G., Sun, Y., He, Y., Ji, C., Hu, B., miR-26a promoted by interferon-alpha inhibits hepatocellular carcinoma proliferation and migration by blocking EZH2. Genet. Test. and Mol. Biomarkers 19 (2015), 30–36.
27. [27] Yang, X., Liang, L., Zhang, X.F., Jia, H.L., Qin, Y., Zhu, X.C., Gao, X.M., Qiao, P., Zheng, Y., Sheng, Y.Y., Wei, J.W., Zhou, H.J., Ren, N., Ye, Q.H., Dong, Q.Z., Qin, L.X., MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology 58 (2013), 158–170.
28. [28] Lu, J., He, M.L., Wang, L., Chen, Y., Liu, X., Dong, Q., Chen, Y.C., Peng, Y., Yao, K.T., Kung, H.F., Li, X.P., MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res. 71 (2011), 225–233.
29. [29] Alajez, N.M., Shi, W., Hui, A.B., Bruce, J., Lenarduzzi, M., Ito, E., Yue, S., O'Sullivan, B., Liu, F.F., Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell. Death. Dis., 1, 2010, e85.
30. [30] Huse, J.T., Brennan, C., Hambardzumyan, D., Wee, B., Pena, J., Rouhanifard, S.H., Sohn-Lee, C., le Sage, C., Agami, R., Tuschl, T., Holland, E.C., The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes. Dev. 23 (2009), 1327–1337.
31. [31] Qian, X., Zhao, P., Li, W., Shi, Z.M., Wang, L., Xu, Q., Wang, M., Liu, N., Liu, L.Z., Jiang, B.H., MicroRNA-26a promotes tumor growth and angiogenesis in glioma by directly targeting prohibitin. Cns Neurosci. Ther. 19 (2013), 804–812.
32. [32] Wang, L.J., Zhang, K.L., Zhang, N., Ma, X.W., Yan, S.W., Cao, D.H., Shi, S.J., Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma. Oncotarget 6 (2015), 18631–18640.
33. [33] Zhang, J.Q., Han, C., Wu, T., MicroRNA-26a promotes cholangiocarcinoma growth by activating beta-catenin. Gastroenterology 143 (2012), 246–U467.
34. [34] Deng, M., Tang, H.L., Lu, X.H., Liu, M.Y., Lu, X.M., Gu, Y.X., Liu, J.F., He, Z.M., MiR-26a suppresses tumor growth and metastasis by targeting FGF9 in gastric cancer. PLoS One, 8, 2013.
35. [35] Ding, K., Banerjee, A., Tan, S., Zhao, J., Zhuang, Q., Li, R., Qian, P., Liu, S., Wu, Z.S., Lobie, P.E., Zhu, T., Artemin a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells. J. Biol. Chem. 289 (2014), 16057–16071.
36. [36] Kong, X., Li, G., Yuan, Y., He, Y., Wu, X., Zhang, W., Wu, Z., Chen, T., Wu, W., Lobie, P.E., Zhu, T., MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS One, 7, 2012, e41523.
37. [37] Ding, Z.Y., Jin, G.N., Wang, W., Chen, W.X., Wu, Y.H., Ai, X., Chen, L., Zhang, W.G., Liang, H.F., Laurence, A., Zhang, M.Z., Datta, P.K., Zhang, B., Chen, X.P., Reduced expression of transcriptional intermediary factor 1 gamma promotes metastasis and indicates poor prognosis of hepatocellular carcinoma. Hepatology 60 (2014), 1620–1636.
38. [38] Tapia, O., Riquelme, I., Leal, P., Sandoval, A., Aedo, S., Weber, H., Letelier, P., Bellolio, E., Villaseca, M., Garcia, P., Roa, J.C., The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch. 465 (2014), 25–33.
39. [39] Stewart, A.L., Mhashilkar, A.M., Yang, X.H., Ekmekcioglu, S., Saito, Y., Sieger, K., Schrock, R., Onishi, E., Swanson, X., Mumm, J.B., Zumstein, L., Watson, G.J., Snary, D., Roth, J.A., Grimm, E.A., Ramesh, R., Chada, S., PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol. Med. 8 (2002), 451–461.
40. [40] Yang, L., Kuang, L.G., Zheng, H.C., Li, J.Y., Wu, D.Y., Zhang, S.M., Xin, Y., PTEN encoding product: a marker for tumorigenesis and progression of gastric carcinoma. World J. Gastroenterol. 9 (2003), 35–39.
41. [41] Liu, B., Wu, X., Wang, C., Liu, Y., Zhou, Q., Xu, K., MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. Biochim. Biophys. Acta 1822 (2012), 1692–1704.
42. [42] Guo, P., Nie, Q., Lan, J., Ge, J., Qiu, Y., Mao, Q., C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells. Biochem. Biophys. Res. Commun. 441 (2013), 186–190.
43. [43] Zou, Z.J., Fan, L., Wang, L., Xu, J., Zhang, R., Tian, T., Li, J.Y., Xu, W., miR-26a and miR-214 down-regulate expression of the PTEN gene in chronic lymphocytic leukemia, but not PTEN mutation or promoter methylation. Oncotarget 6 (2015), 1276–1285.
44. [44] Mester, J., Eng, C., When overgrowth bumps into cancer: the PTEN-opathies. American journal of medical genetics. Part C Semin. Med. Genet. 163C (2013), 114–121.
45. [45] Ma, F., Zhang, J., Zhong, L., Wang, L., Liu, Y., Wang, Y., Peng, L., Guo, B., Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/beta-catenin signaling. Gene 535 (2014), 191–197.
46. [46] Wang, F., Li, T., Zhang, B., Li, H., Wu, Q., Yang, L., Nie, Y., Wu, K., Shi, Y., Fan, D., MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. Biochem. Biophys. Res. Commun. 434 (2013), 688–694.
47. [47] Yang, T.S., Yang, X.H., Chen, X., Wang, X.D., Hua, J., Zhou, D.L., Zhou, B., Song, Z.S., MicroRNA-106b in cancer-associated fibroblasts from gastric cancer promotes cell migration and invasion by targeting PTEN. FEBS Lett. 588 (2014), 2162–2169.
48. [48] Goodwin, C.R., Lal, B., Ho, S., Woodard, C.L., Zhou, X., Taeger, A., Xia, S., Laterra, J., PTEN reconstitution alters glioma responses to c-Met pathway inhibition. Anticancer Drugs 22 (2011), 905–912.
49. [49] Li, Y., Guessous, F., DiPierro, C., Zhang, Y., Mudrick, T., Fuller, L., Johnson, E., Marcinkiewicz, L., Engelhardt, M., Kefas, B., Schiff, D., Kim, J., Abounader, R., Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Mol. Cancer Ther. 8 (2009), 376–385.
50. [50] Hertzler-Schaefer, K., Mathew, G., Somani, A.K., Tholpady, S., Kadakia, M.P., Chen, Y., Spandau, D.F., Zhang, X., Pten loss induces autocrine FGF signaling to promote skin tumorigenesis. Cell Rep. 6 (2014), 818–826.
51. [51] Guntur, A.R., Reinhold, M.I., Cuellar, J. Jr., Naski, M.C., Conditional ablation of Pten in osteoprogenitors stimulates FGF signaling. Development 138 (2011), 1433–1444.